Mogroside IV - Canopus BioPharma
Alternative Names: CB-5300; Mogroside-IV; MogrovirLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Canopus BioPharma
- Class Antivirals; Triterpenoid sapogenins
- Mechanism of Action Immunostimulants; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue; Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-C(Combination therapy, Treatment-naive) in China (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dengue in USA (PO)
- 23 Sep 2015 No recent reports on development identified - Phase-II for Hepatitis C in USA (PO)